Clinical trials · Washington, D.C., DC
Advanced or Metastatic Solid Tumors clinical trials in Washington, D.C.
We’re tracking 517 recruiting advanced or metastatic solid tumors studies with a site in or near Washington, D.C. — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT05950139RecruitingPhase 1/Phase 2
Vaccine to help stop lung cancer drug resistance
This early-phase study tests a personalized peptide vaccine designed to help prevent advanced ALK-positive non-small cell lung cancer from developing resistance to current targeted medicines. If you are stable on an ALK drug and don’t already have the specific resistance changes the vaccine targets, it may help your cancer stay controlled longer.
Baltimore, MarylandAges 18 years+ - NCT04617522RecruitingPhase 1
Sacituzumab govitecan for advanced cancers with moderate liver issues
This Phase 1 study tests how safe and tolerable sacituzumab govitecan is for people with advanced or metastatic solid tumors who also have moderate liver impairment. It aims to find the right dosing so the treatment can be used more safely in this liver-risk group.
Baltimore, MarylandAges 18 years+ - NCT07281768RecruitingPhase 2
Chemo and immunotherapy for locally advanced rectal cancer
This trial tests whether adding two types of immunotherapy (cemiplimab with either fianlimab or REGN7075) to standard chemotherapy is safe and effective for people with locally advanced rectal cancer that has not been treated before. It may help shrink the tumor enough to allow surgery that preserves the ability to control bowel movements.
Baltimore, MarylandAges 18 years+ - NCT06926868RecruitingPhase 2/Phase 3
Study of a new drug versus chemotherapy for advanced triple-negative breast cancer
This trial tests a new investigational drug called izalontamab brengitecan against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. The goal is to see if the new drug works better at shrinking or slowing the cancer.
Baltimore, MarylandAges 18 years+ - NCT05283226RecruitingPhase 2
Oral anti-cancer pill plus paclitaxel after immunotherapy failure
This Phase 2 trial studies an oral study drug (NRC-2694-A) given with paclitaxel to treat head and neck squamous cell cancer that has come back or spread after immunotherapy. It tests whether this combination is safer and works better than expected for people whose cancer progressed on immune checkpoint inhibitors.
Baltimore, MarylandAges 18 years+ - NCT06027086RecruitingPhase 1/Phase 2
Combination drug therapy for advanced fibrolamellar carcinoma
This trial tests a new combination of two drugs—DRP-104 and durvalumab—to see if they can shrink or slow advanced fibrolamellar carcinoma, a rare liver cancer. It is for patients whose cancer has gotten worse even after immunotherapy treatment.
Baltimore, MarylandAges 12 years+ - NCT06934538RecruitingPhase 1/Phase 2
Immunotherapy trial for advanced colorectal cancer
This trial tests a new immunotherapy drug (STC-1010) for people with colorectal cancer that cannot be removed by surgery or has spread. It aims to see if the drug can shrink tumors or slow the disease.
Baltimore, MarylandAges 18–75 - NCT06744790Recruiting
Predicting breathing trouble after surgery with a new sensor
This trial tests a new sensor that monitors your breathing to predict if you might have trouble after surgery. It is for people who are staying overnight in the hospital and getting extra oxygen through a face mask.
Baltimore, MarylandAges 18 years+ - NCT05902988RecruitingPhase 1/Phase 2
Study of VLS-1488 for advanced cancers
This early-phase study tests VLS-1488, a new cancer medicine, in people with advanced cancers that have limited treatment options. It may help by finding a safe dose and whether it can shrink or control tumors.
Baltimore, MarylandAges 18 years+ - NCT07621718RecruitingPhase 3
Zoldonrasib plus chemotherapy for metastatic pancreatic cancer with KRAS mutation
This trial tests whether adding a new drug called zoldonrasib to standard chemotherapy works better than chemotherapy alone for pancreatic cancer that has spread and has a specific KRAS G12D mutation. The goal is to see if this combination helps patients live longer and control their cancer better.
Baltimore, MarylandAges 18 years+ - NCT07327489Recruiting
Live tumor biopsy study to predict immunotherapy response
This trial studies how well immunotherapy might work by analyzing fresh tumor biopsies. It may help predict which treatments are best for your cancer.
Frederick, MarylandAges 18 years+ - NCT07181161RecruitingPhase 1/Phase 2
Testing a new drug for metastatic prostate cancer
This trial tests an investigational drug (AZD0516) alone or with other treatments in men with prostate cancer that has spread to other parts of the body and is no longer responding to hormone therapy. It aims to see if the drug can help control the cancer.
Towson, MarylandAges 18–130 - NCT06524544RecruitingPhase 3
Pembrolizumab and sacituzumab govitecan for advanced bladder cancer
This trial tests a new drug combination (pembrolizumab and sacituzumab govitecan) against standard treatment for advanced bladder cancer that has spread or cannot be removed by surgery. It's for people who have already tried an immunotherapy drug like pembrolizumab and another drug called enfortumab vedotin.
Fredericksburg, VirginiaAges 18 years+
Hear when a new Advanced or Metastatic Solid Tumors trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Advanced or Metastatic Solid Tumors trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting advanced or metastatic solid tumors studies listed above.
- Johns Hopkins University · 4 studies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 2 studies
- Frederick Health Hospital
- Hematology Oncology Associates of Fredericksburg
- Local Institution - 1035
- Research Site
- University of Maryland
- University of Maryland Greenebaum Comprehensive Cancer Center
What taking part in a advanced or metastatic solid tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there advanced or metastatic solid tumors clinical trials near Washington, D.C.?
- Yes. We're currently tracking 517 recruiting advanced or metastatic solid tumors studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced or metastatic solid tumors study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced or metastatic solid tumors studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.